Who
Barbara-Jean Anne Bormann-Kennedy
Director
Company insider
Files Form 4 as: Director, Xeris Biopharma Holdings; Director, Xeris Pharmaceuticals.
In numbers
- Trades disclosed
- 23
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $301K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 27 Feb 2019
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Dec 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $98K16,000 at $6.09 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —24,193 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | $203K32,996 at $6.15 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | $203K32,996 at $6.15 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $97K16,000 at $6.09 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —24,193 at $0.00 | filing |
| 12 Dec 2025filed 15 Dec 2025 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $106K15,000 at $7.09 | filing |
| 4 Jun 2025filed 4 Jun 2025 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 5 Jun 2024filed 5 Jun 2024 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Jun 2023filed 7 Jun 2023 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —42,500 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | $32K15,000 at $2.10 | filing |
| 5 Oct 2021filed 5 Oct 2021 | Xeris Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —19,650 | filing |
| 5 Oct 2021filed 5 Oct 2021 | Xeris Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 5 Oct 2021filed 5 Oct 2021 | Xeris Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —11,228 | filing |
| 5 Oct 2021filed 5 Oct 2021 | Xeris Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —11,228 | filing |
| 5 Oct 2021filed 5 Oct 2021 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,650 | filing |
| 5 Oct 2021filed 5 Oct 2021 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 | filing |
| 5 Oct 2021filed 5 Oct 2021 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,228 | filing |
| 5 Oct 2021filed 5 Oct 2021 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,228 | filing |
News
Critical Contrast: Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS)XERS · tickerreport.com · 21 Oct 2026Head-To-Head Survey: Organon & Co. (NYSE:OGN) versus Xeris Biopharma (NASDAQ:XERS)XERS · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Barbara-Jean Anne Bormann-Kennedy; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.